These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36278961)

  • 1. Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer.
    Peng K; Zhang F; Wang Y; Sahgal P; Li T; Zhou J; Liang X; Zhang Y; Sethi N; Liu T; Zhang H; Bass AJ
    Clin Cancer Res; 2023 Jan; 29(1):197-208. PubMed ID: 36278961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent RhoGAP gene fusion CLDN18-ARHGAP26 promotes RHOA activation and focal adhesion kinase and YAP-TEAD signalling in diffuse gastric cancer.
    Zhang F; Sahu V; Peng K; Wang Y; Li T; Bala P; Aitymbayev D; Sahgal P; Schaefer A; Der CJ; Ryeom S; Yoon S; Sethi N; Bass AJ; Zhang H
    Gut; 2024 Jul; 73(8):1280-1291. PubMed ID: 38621923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gain-of-Function
    Zhang H; Schaefer A; Wang Y; Hodge RG; Blake DR; Diehl JN; Papageorge AG; Stachler MD; Liao J; Zhou J; Wu Z; Akarca FG; de Klerk LK; Derks S; Pierobon M; Hoadley KA; Wang TC; Church G; Wong KK; Petricoin EF; Cox AD; Lowy DR; Der CJ; Bass AJ
    Cancer Discov; 2020 Feb; 10(2):288-305. PubMed ID: 31771969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors.
    Marlowe TA; Lenzo FL; Figel SA; Grapes AT; Cance WG
    Mol Cancer Ther; 2016 Dec; 15(12):3028-3039. PubMed ID: 27638858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways.
    Zhang H; Shao H; Golubovskaya VM; Chen H; Cance W; Adjei AA; Dy GK
    Br J Cancer; 2016 Jul; 115(2):203-11. PubMed ID: 27336608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Focal adhesion kinase-An emerging viable target in cancer and development of focal adhesion kinase inhibitors.
    Chauhan A; Khan T
    Chem Biol Drug Des; 2021 Mar; 97(3):774-794. PubMed ID: 33191630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent progress on FAK inhibitors with dual targeting capabilities for cancer treatment.
    Wu X; Wang J; Liang Q; Tong R; Huang J; Yang X; Xu Y; Wang W; Sun M; Shi J
    Biomed Pharmacother; 2022 Jul; 151():113116. PubMed ID: 35598365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models.
    Fang DD; Tao R; Wang G; Li Y; Zhang K; Xu C; Zhai G; Wang Q; Wang J; Tang C; Min P; Xiong D; Chen J; Wang S; Yang D; Zhai Y
    BMC Cancer; 2022 Jul; 22(1):752. PubMed ID: 35820889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EXOC4 Promotes Diffuse-Type Gastric Cancer Metastasis via Activating FAK Signal.
    Li H; Fu X; Zhao J; Li C; Li L; Xia P; Guo J; Wei W; Zeng R; Wu J; Sun Y; Huang L; Wang X
    Mol Cancer Res; 2022 Jul; 20(7):1021-1034. PubMed ID: 35471457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review.
    Shanthi E; Krishna MH; Arunesh GM; Venkateswara Reddy K; Sooriya Kumar J; Viswanadhan VN
    Expert Opin Ther Pat; 2014 Oct; 24(10):1077-100. PubMed ID: 25113248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear focal adhesion kinase induces APC/C activator protein CDH1-mediated cyclin-dependent kinase 4/6 degradation and inhibits melanoma proliferation.
    Murphy JM; Jeong K; Ahn EE; Lim SS
    J Biol Chem; 2022 Jun; 298(6):102013. PubMed ID: 35525274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors.
    Yamaguchi H; Takanashi M; Yoshida N; Ito Y; Kamata R; Fukami K; Yanagihara K; Sakai R
    Cancer Sci; 2014 May; 105(5):528-36. PubMed ID: 24612061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Focal adhesion kinase inhibitors in the treatment of solid tumors: Preclinical and clinical evidence.
    Quispe PA; Lavecchia MJ; León IE
    Drug Discov Today; 2022 Feb; 27(2):664-674. PubMed ID: 34856395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Advances of Small Molecule Focal Adhesion Kinase (FAK) Inhibitors as Promising Anticancer Therapeutics.
    Lv P; Chen K; Zhu HL
    Curr Med Chem; 2021 Oct; 28(34):6977-6989. PubMed ID: 33797359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy.
    Heffler M; Golubovskaya VM; Dunn KM; Cance W
    Cancer Biol Ther; 2013 Aug; 14(8):761-72. PubMed ID: 23792569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focal adhesion kinase regulates collagen I-induced airway smooth muscle phenotype switching.
    Dekkers BG; Spanjer AI; van der Schuyt RD; Kuik WJ; Zaagsma J; Meurs H
    J Pharmacol Exp Ther; 2013 Jul; 346(1):86-95. PubMed ID: 23591997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK).
    Lu Y; Sun H
    J Med Chem; 2020 Dec; 63(23):14382-14403. PubMed ID: 33058670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and Characterization of Selective FAK Inhibitors and PROTACs with In Vivo Activity.
    Koide E; Mohardt ML; Doctor ZM; Yang A; Hao M; Donovan KA; Kuismi CC; Nelson AJ; Abell K; Aguiar M; Che J; Stokes MP; Zhang T; Aguirre AJ; Fischer ES; Gray NS; Jiang B; Nabet B
    Chembiochem; 2023 Oct; 24(19):e202300141. PubMed ID: 37088717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse Gastric Cancer: A Comprehensive Review of Molecular Features and Emerging Therapeutics.
    Wu LW; Jang SJ; Shapiro C; Fazlollahi L; Wang TC; Ryeom SW; Moy RH
    Target Oncol; 2024 Nov; 19(6):845-865. PubMed ID: 39271577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.
    Lu H; Wang L; Gao W; Meng J; Dai B; Wu S; Minna J; Roth JA; Hofstetter WL; Swisher SG; Fang B
    Mol Cancer Ther; 2013 Dec; 12(12):2864-73. PubMed ID: 24130049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.